A 72-Year-Old Woman with Single Lineage Dysplasia MDS

Jamie L. Koprivnikar, MD, presents the case of a 72-year-old woman diagnosed with single lineage dysplasia myelodysplastic syndrome and shares her initial impressions.

Dr Jamie L. Koprivnikar describes her general approaches to diagnosing and risk stratifying patients with myelodysplastic syndrome, and how she differentiates high-risk and low-risk disease.

Jamie L. Koprivnikar, MD, details how her treatment approaches differ for patients with low-risk versus high-risk myelodysplastic syndrome.

Dr Jamie L. Koprivnikar comments on the currently unmet needs for patients with low-risk myelodysplastic syndrome in the front-line setting.

Jamie L. Koprivnikar, MD, reviews luspatercept as a treatment option in myelodysplastic syndrome and the adverse events most frequently seen with her patients in clinical practice.

A review of the rationale and study design of the phase 3 COMMANDS trial and subsequent subgroup analysis data recently presented at the ASCO and EHA 2023 Annual Meetings.

Dr Jamie L. Koprivnikar discusses the rationale surrounding luspatercept as a potential first-line treatment option for patients with myelodysplastic syndrome, and if it would have been an appropriate therapy for the patient in the presented case study.

Jamie L. Koprivnikar, MD, closes by sharing some future insights and remaining unmet needs for patients with myelodysplastic syndrome.